1120
CLINICAL REPORT
Topical Oxybutynin 10% Gel for the Treatment of Primary Focal
Hyperhidrosis: A Randomized Double-blind Placebo-controlled Split
Area Study
Ofir ARTZI 1 , Christophoros LOIZIDES 1 , Eyal ZUR 2 and Eli SPRECHER 1,3
1
Department of Dermatology, Tel Aviv Medical Center, Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, 2 Central Compounding
Laboratory, Petach-Tikva, and 3 Department of Human Molecular Genetics & Biochemistry, Sackler Faculty of Medicine, Tel Aviv University,
Tel Aviv, Israel
Limited efficacy, costs, side-effects and complications
are issues of concern for most current therapeutic mo-
dalities for focal hyperhidrosis. This study evaluated
the efficacy of topical oxybutynin 10% gel in treating
61 patients with primary focal hyperhidrosis. The gel
was applied to the right or left axilla, palms or soles
vs. a placebo compound to the contralateral side for 30
days. A blinded visual grading of the change in starch-
iodine tests was performed by 2 non-involved physici-
ans. The Hyperhidrosis Disease Severity Scale (HDSS)
and Dermatology Life Quality Index (DLQI) questionn-
aires were administered before and after treatment.
The patients rated their satisfaction with treatment.
Fifty-three patients completed the 4-week treatment.
Sweat reduction in the drug-treated sweating areas
was higher than in the control-treated areas. There
was a significant mean improvement in pre- and post-
treatment HDSS and DQLI (p = 0.001 for both). Thirty-
nine subjects (74%) reported moderate-to-high satis-
faction. Twice-daily topical application of oxybutynin
10% gel appears to be an effective, safe and well-tole-
rated treatment for focal primary hyperhidrosis.
Key words: focal hyperhidrosis; axillary; palmar; plantar; topi-
cal oxybutynin.
Accepted Jun 22, 2017; Epub ahead of print Jun 27, 2017
Acta Derm Venereol 2017; 97: 1120–1124.
Corr: Ofir Artzi, Department of Dermatology, Tel Aviv Medical Center, 6
Weizman Street, Tel Aviv, 6423906, Israel. E-mail: [email protected]
H
yperhidrosis is a common condition, affecting
up to 3% of the population, and has a significant
impact on many asp